Nuveen Asset Management LLC Purchases 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Nuveen Asset Management LLC lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 13.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,903,442 shares of the company's stock after buying an additional 228,380 shares during the period. Nuveen Asset Management LLC owned approximately 1.28% of Xeris Biopharma worth $6,453,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after acquiring an additional 651,481 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $2,014,000. Millennium Management LLC increased its stake in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after purchasing an additional 500,120 shares in the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $1,610,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS traded down $0.37 during trading on Tuesday, reaching $4.68. The company had a trading volume of 3,648,557 shares, compared to its average volume of 1,961,810. The firm's fifty day moving average is $4.63 and its 200 day moving average is $4.05. The firm has a market capitalization of $731.88 million, a PE ratio of -10.40 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a twelve month low of $2.03 and a twelve month high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners lifted their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. Oppenheimer lifted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Craig Hallum lifted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.47% of the company's stock.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.